535
Views & Citations10
Likes & Shares
The present work describes a new novel method for the
extraction of Stromal Vascular Fraction (SVF) from adipose tissue and its
significant clinical applications. The technique involves using a simple
acoustic waves (acoustic bio modulation) to activate the separation of Stromal
Vascular Fraction (SVF) from lipoaspirate solution. Further, it allows
producing active viable cells in a short time and expenses. In addition, it is
simple, not complicated, and non- invasive compared with others so far
available. Up to our knowledge the technique used in this work can be described
as a new. It has many advantages over other already described methods including
the enzymatic and the mechanical methods.
Keywords:
Stromal vascular fraction, Adipose tissue, Acoustic waves, Enzymatic
methods, Mechanical methods
INTRODUCTION
The stromal
vascular fluid (SVF) can be defined as a heterogeneous population of freshly
isolated cells from adipose tissue. This cell population comprises many
different cell types, such as mature endothelial cells, endothelial
progenitors, pericytes, fibroblasts, mesenchymal stromal cells, macrophages and
others, but excludes mature adipocytes. Conversely Adipose Derived Stem Cells
(ADCSs) are cells found in adipose tissue and have shown to have properties of
self-renewal and differentiation to several different cell types [1,2].
In the last 15
years we have seen a huge increase in the number of publications showing basic
research and clinical studies using adipose-derived cells. There are a variety
of methods available for the isolation of SVF cells, but overall they fall into
two general categories: those which use proteolytic enzymes (collagenase) to
dissociate lipoaspirate (enzymatic methods) and those which do not use
proteolytic enzymes (mechanical methods).
Enzymatic
methods yield significantly more nucleated cells from an equivalent weight of
tissue than mechanical methods and tend to isolate a lower frequency of cells
with hematopoietic origin and a higher frequency of stromal/stem cells [3,4].
Mechanical methods include techniques such as washing, shaking, incubation and
centrifugation in order to separate stromal cell populations from lipoaspirate
samples. However, mechanical methods offer the advantage of being less
expensive and time consuming than enzymatic method.
The current
work was undertaken to use some what a new technique that have some advantages
over the enzymatic and the mechanical methods for the extraction of SVF from
adipose tissue. Further, we wanted to see its clinical applications in four
patients suffering from Osteoarthritis (OA) and Multiple Sclerosis (MS).
PATIENTS AND METHODS
Four patients
of both sexes were enrolled in this study from October to December 2018. Two
female patients aged 56 and 65 years old were suffering from grade 3 knee and
hips OA. The other 2 patients were suffering from MS; 1 female
The two patients with knee and hip
osteoarthritis were injected with 5 ml of the lipoaspirate fluid intra-particularly
on 8 December 2018; whereas the other two MS patients were injected with 20 ml
of the fluid aspirate intravenously on 16 October 2018.
The present
method includes mini lipoaspiration to remove a homogenous population of cells
from the fluid phase by local anesthesia to the skin. The new technique
included:
1. Minilipoaspirate
from the adult human abdominal subcutaneous tissue using local anesthesia
(xylocaine 1%) after getting patient consent.
2. Infusion
of a tumescent solution containing 250 ml of normal physiological saline 0.9%
with 20 ml of xylocaine 1% with 10 ml of sodium bicarbonate (840
milliequivalent) and adrenaline 1/1000 1 ml, the whole solution is divided into
2 parts each to one abdominal side infused using special lipoaspiration cannula
with small caliber opening to infuse the solution subcutaneously by
reintroduction of the cannula frequently to get even homogenous solution
distribution.
3. We
wait for 20 min then we aspirate the solution using special lipoaspiration
cannula with wide bore to get maximum amount of solubilized subcutaneous fat
from both abdominal sides.
4. The
mean volume of the lipoaspirate is 100 ml from both abdominal sides.
5. We
injected the solution using wide bore needle in a 100 ml of sterile plastic bag
for clinical uses.
6. We
put the acoustic wave’s probe of 10 cm diameter over the bag for 10 min, at the
end we got a bilayer solution the upper one is the lipid layer and a pink lower
solution.
7. We
put the solution hanging over a stand for 5 min to allow gravity to separate
the upper and lower layers.
8. We
connected the solution bag to a 170 µm filter to pass the lower fluid layer
through.
9. After
collecting the lower layer of the solution we centrifuged it for 5 min (5000
rpm) with counter balance tube.
10. The
stromal vascular fraction is extracted from the bottom of the tube using long
spinal needle. We got a homogenous population of cells from the fluid phase and
therefore, by using this new technique we did not capture of a specific
population from heterogeneous mixture. Further, this fluid lipoaspirate allows
the separation of two different tissue densities, because this method resulting
into separation of 2 layers with resulting clear demarcation between adipose
layer above and stromal vascular fraction below. The microscopic examination of
the SVF fraction showed multiple types of cells including pericytes,
periadiposite and mesenchymal T cells and other.
RESULTS
The results of
the present preliminary study showed that the technique adopted in the current
showed some advantages when compared with other already available techniques.
Among these advantages is the amount of aspirate of SVF fraction obtained which
reached up to 25 ml. This technique is rather simple, non-invasive and sterile.
In addition, it produces active viable cells in a short time (10-15 min) and
cheap to use. Further, it separates the different cell density fluids including
the adipose and liquid ones.
Clinically, no
evidence of treatment related adverse events was noted in any patient. Results
show that the benefit reported so far is encouraging especially in two patients
suffering from knee and hip OA using Womac scale (57% reduction). However, no
response so far was reported from two patients suffering from MS.
DISCUSSION
Osteoarthritis is a chronic progressive
degenerative disease associated with cartilage loss and degeneration. Current
treatments are limited and advanced disease relies on total joint replacement.
Total joint replacement may be associated with serious and life threatening
complications including increased risk of infection, thromboembolism,
myocardial infarction, stroke and even death post-surgery. In addition, the
life span of the prosthesis is limited [5].
Recently, several methods are adopted to
treat osteoarthritis using new techniques including injection of SVF and SVF
combined with other techniques.
It has been reported that SVF combined with
Platelet-Rich Plasma (PRP) has a great potential as a therapeutic agent in
regenerative medicine especially in orthopedic conditions. The high numbers of
Mesenchymal Stem Cells (MSCs) in SVF make it a suitable source for cellular
medicine. Preliminary studies suggest that it is a safe and effective method
for treating osteoarthritis. Both qualitative and quantitative measurements
showed statistically significant improvements during the follow up period of 2
years. Additional studies with larger patient numbers and control subjects are
needed to confirm the above results. Another limitation of this study is the
combined effect of two modalities is unclear. Future studies with randomized
groups considering each therapeutic agent separately and combined against a
control are warranted. This clinical study of a combined intra-articular
injection of SVF and PRP into the knee suggests a promising minimally invasive
therapy for OA patients. In the United Kingdom, NICE published guidelines in
May 2014 (‘platelet-rich plasma injections for osteoarthritis of the knee’)
[6]. These state that current evidence on PRP injections for osteoarthritis of
the knee raises no major safety concerns. Nevertheless, the evidence on
efficacy is inadequate in quality. NICE recommends that this procedure should
only be used with special arrangements for clinical governance, consent and
audit or research [6]. They also suggest that any further research into PRP
injections for treating osteoarthritis of the knee should categorically
describe patient selection and take the form of well-designed studies that
compare the procedure against other methods of management. Outcomes should
include knee function scores, patient-reported outcome measures and the timing
of subsequent interventions [6].
On the other hand, MS is a chronic
inflammatory demyelinating disease of the CNS which involves the loss of
myelin-forming oligodendrocytes that can be followed by a spontaneous and an
efficient regenerative process called remyelination [7]. It affects the people
of almost all the ages in many parts of the world, mostly young people,
especially more prevalent in women and among those in northern latitudes.
Relapsing-Remitting Multiple Sclerosis (RRMS) is the most common form of MS.
In 2009, the first trial of Stromal Vascular
Fraction (SVF) isolated from adipose tissue was conducted with 3 progressive
male MS patients. The SVF contains Endothelial Progenitor Cell (EPC), MSCs, T
regulatory cells, endothelial precursor cells, pre-adipocytes, as well as
anti-inflammatory M2 macrophages. The SVF cells were infused by IV and
intrathecal. Infusions were very well tolerated without any patient complaints
or side effects. A couple of months after stem cell infusion their clinical
conditions were improving and their brain MRI had no other new lesions [8].
Adipose-derived Mesenchymal Stem Cells
(ADMSCs) are another source of MSC [9] with the advantage that the samples for
stem cell production can be taken with a minimally invasive lipectomy
procedure. With the exception of a report of 3 patients treated with stromal
vascular fraction (cells from unexpanded adipose samples) [10] and another two
small studies [11,12] the potential of adipose tissue as a source of stem cells
has not been explored. In conclusion, the present study demonstrates that
infusion of ADMSCs is a safe and feasible procedure in patients with SPMS.
Although the study was not powered to determine the efficacy, some hint of
efficacy was observed by the use of MRI and evoked potentials. Larger studies
would be needed to investigate the potential therapeutic benefit of the
technique.
The most pronounced changes following SVF
treatment were the high levels of interleukin-10 in the peripheral blood,
lymphoid and CNS tissues along with the induction of regulatory T cells in the
lymph nodes which indicate potent immunomodulatory effects. The data indicate a
SVF cell effectively ameliorated the EAE immune pathogenesis and supports the
potential use of SVF for treating MS. This is the first evidence, to date, to
elucidate a mechanism of action of SVF treatment in an inflammatory, autoimmune
disease. Our data supports key immunomodulatory signaling between cell
therapies and T cells in this T cell-mediated disease. Together, treatment with
SVF mediated immunomodulatory effects that diminished effector cell activities,
promoted regulatory T cells and reduced neuroinflammation [13].
The results of the current study showed some
advantages using the new technique. This technique resulted in the isolation of
adult stem cells in addition to other already known cells that can be isolated
from the SVF fraction rather than other sources of obtaining adult stem cells
such as using bone marrow, dental progenitor and endometrial tissue. Second,
this method resulted into separation of two layers with no clumps and clots.
Furthermore, it allowed separation of viable cells within a short time and with
no contamination. Furthermore, using this technique provides more energy to the
fluid and this may lead to yield or produce active viable cells within a short
time and expenses. Clinically, we used the cells harvested by this technique on
four patients. Despite the short observation time, the results of the present
study suggest that using SVF therapy for both OA and MS patients are safe and
well tolerated and without any complications or side effects. Second, it is
premature to discuss the outcome of the potential effect of using it in the
patients under treatment. Our preliminary results showed that intra articular
injection of freshly isolated SVH cells obtained from adipose tissue in the
first two patients suffering knee and hip osteoarthritis, are encouraging and
there is a good response so far obtained [14].
These patients were injected with fluid
lipoaspirate only on 8 December 2018 and they showed good response after two
months following the injection. However, they are under careful follow up and
we hope to do full scans including magnetic resonance imaging after 4 and 6
months and other scans to see the outcome. It seems that our preliminary
results are consistent with results of other investigators who reported the
benefit at 6 months. Yet, a long-term follow up data is required.
On the other hand, it is not surprising not
to observe any response in the two MS patients simply because these two
patients were injected with the fluid lipoaspirate only two months ago, i.e., 8
December 2018. In order to investigate the outcome and the potential
therapeutic benefits on MS patients a couple of months (6-18) are needed.
Finally, we would like to indicate that
current therapy in our laboratories are in progress using SVF in combination
with a new potentially active anti-inflammatory and immunomodulatory agent and
we hope to disclose these data later [15].
CONCLUSION
Our reports indicate that our preliminary
results are consistent with results of other source and investigators who
reported the benefit at 6 months. Yet, a long-term follow up data is required.
GUARANTOR
The corresponding author is a guarantor of
submission.
CONFLICT OF
INTEREST
The authors declare no conflict of interest.
1.
Murphy MB, Moncivais K, Caplan AL (2013) Mesenchymal stem
cells: Environmentally responsive therapeutics for regeneration medicine. Exp
Mol Med 45: e54.
2.
Bourin P, Bunnell BA, Casteilla L, Dominici M, Katz AJ,
et al. (2013) Stromal cells from the adipose tissue-derived stromal cells/stem
cells: A joint statement of the International Federation for Adipose
Therapeutics and Science (IFATS) and the International Society for Cellular
Therapy (ICST). Ctrotherapy 15: 641-648.
3.
Markarian CF, Frey GZ, Silveira MD, Chem EM, Milani AR,
et al. (2014) Isolation of adipose-derived stem cells: A comparison among
different methods. Biotechnol Lett 36: 693-702.
4.
Baptisa LS, do Amaral RJ, Carias RB, Aniceto M,
Claudio-da-Silva C, et al. (2009) An alternative method for the isolation of
mesenchymal stromal cells derived from lipoaspirate samples. Cytotherapy 11:
706-715.
5.
Schrama JC, Espehaug B, Hallan G, Engesaeter E (2010)
Risk of revision for infection in primary total hip and knee arthroplasty in
patients with rheumatoid arthritis compared with osteoarthritis: A prospective,
population-based study on 108,786 hip and knees joint arthroplasties from the
Norwegian Arthoplasty Register. Arthritis Care Res 62: 473-479.
6.
(2017) NICE Platelet-rich plasma injections for
osteoarthritis of the knee NICE interventional procedure guidance IPG491.
Available at: https://www.nice.org.uk/guidance/ipg491
7.
Minagar A, Jy W, Jimenez JJ, Alexander JS (2006) Multiple
sclerosis as a vascular disease. Neurol Res
28: 230-235.
8.
Riordan NH, Ichim TE, Min WP, Wang H, Solano F, et al.
(2009) Non-expanded adipose stromal vascular fraction cell therapy for multiple
sclerosis. J Transl Med 7: 29.
9.
Gimble JM, Katz AJ, Bunnell BA (2007) Adipose-derived
stem cells for regenerative medicine. Circ Res 100: 1249-1260.
10.
Riordan NH, Ichim TE, Min WP, Wang H, Solano F, et al.
(2009) Non-expanded adipose stromal vascular fraction cell therapy for multiple
sclerosis. J Transl Med 7: 29.
11.
Ra JC, Kang SK, Shin IS, Park HG, Joo SA, et al. (2011)
Stem cell treatment for patients with autoimmune disease by systemic infusion
of culture-expanded autologous adipose tissue derived mesenchymal stem cells. J
Transl Med 9: 181.
12.
Stepien A, Dabrowska NL, Maciagowska M, Macoch RP,
Zolocinska A, et al. (2016) Clinical application of autologous adipose stem
cells in patients with multiple sclerosis: Preliminary results. Mediators
Inflamm 2016: 1-5.
13.
Shahbeigi S, Sepehry AA, Oger J (2014) The use of
mesenchymal stems cells in the treatment of MS: An overview of open labels and
on-going studies. J Neurol Neurophysiol 5: 4.
14.
Bansal H, Comella K, Leon J, Verma P, Agrawal D, et al.
(2017) Intra-articular injection in the knee of adipose derived stem cells
(stromal vascular fraction) and platelet rich plasma for osteoarthritis. J
Transl Med 15: 141.
15.
Damia E, Chicharro D, Lopez S, Cuervo B, Rubio M, et al.
(2018) adipose derived mesenchymal stem cells: Are they a good therapeutic
strategy for osteoarthritis? Review open access article. Int J Mol Sci 19:
1926.
QUICK LINKS
- SUBMIT MANUSCRIPT
- RECOMMEND THE JOURNAL
-
SUBSCRIBE FOR ALERTS
RELATED JOURNALS
- Journal of Ageing and Restorative Medicine (ISSN:2637-7403)
- International Journal of Diabetes (ISSN: 2644-3031)
- Journal of Blood Transfusions and Diseases (ISSN:2641-4023)
- Advance Research on Endocrinology and Metabolism (ISSN: 2689-8209)
- Chemotherapy Research Journal (ISSN:2642-0236)
- Journal of Allergy Research (ISSN:2642-326X)
- Advance Research on Alzheimers and Parkinsons Disease